FDA accepts Shionogi’s ensitrelvir (Xocova) NDA for review as the first oral therapy for the prevention of COVID-19 following exposure
Shionogi & Co., Ltd. announced the FDA has accepted for review a New Drug Application (NDA) from Shionogi Inc., its US subsidiary for ensitrelvir (Xocova, enensitrelvir fumaric acid,… read more.
